

BRAIN DISEASE SITE COMMITTEE MEETING

CHELSEA HOTEL, TORONTO, ON
 CARLYLE ROOM,
 SATURDAY, APRIL 26, 2025 9:00 AM – 12:00 PM
 CO-CHAIRS : DR. DAVID ROBERGE & DR. MARSHALL PITZ
 SENIOR INVESTIGATOR: DR. CHRIS O'CALLAGHAN

CME Credits: Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To cite and analyze recent results of clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group relevant to CNS malignancies.
- To summarize recent developments in molecular biology and therapeutics research, as related to CNS malignancies.
- To interpret and address, through clinical and translational research, the disease burden associated with CNS malignancies in Canada.
- To interpret and apply new clinical trial methodologies in the field of clinical research in CNS malignancies.

9:00 am	Welcome and Introductions	Dr. M. Pitz Dr. D. Roberge
9:05 am	Approved Trials/Trials in Progress	
	<ul style="list-style-type: none"> • CE.9 / LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies 	Dr. M. Pitz
	<ul style="list-style-type: none"> • CE.7: A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases 	Dr. D. Roberge
9:35 am	Newly Approved Trials Pending Activation	
	<ul style="list-style-type: none"> • CE.10 (EORTC BTG 2427): Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (The VIGOR Trial) 	Dr. M. Pitz
9:50 am	Brain Working Group & Emerging Concepts	
	<ul style="list-style-type: none"> • A Randomized controlled trial of temozolomide chronotherapy in newly diagnosed GBM – Survey Results and Update of Pilot Study 	Dr. T. Ng
	<ul style="list-style-type: none"> • Fecal microbiota transplantation (FMT) in recurrent GBM: A feasibility, safety, and window-of-opportunity study - Update 	Dr. T. Ng
	<ul style="list-style-type: none"> • Dose escalated radiotherapy for atypical meningioma 	Dr K. Liang Zeng
	<ul style="list-style-type: none"> • MR-Linac On-Line Weekly Adaptive Radiotherapy for High Grade Glioma (HGG): Results from the UNITED Single Arm Phase II Trial & Next Steps 	Dr. J. Detsky
10:30 am	Refreshment Break	
11:00 am	Update of CCS Breakthrough Grant: Developing a comprehensive strategy to implement predictive and targetable biomarkers of primary and metastatic brain tumors	Dr. G. Zadeh
11:15 am	IND Committee Update & Emerging Concepts	Dr. R. Harrison
11:30 am	Update of NCTN Trial Activities/Approved Trials	Dr. M. Pitz Dr. D. Roberge
	Adjourn	





Canadian Cancer Society
Société canadienne du cancer

CCTG is a CCS national program.